Blueprint
 
FORM 6-K
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
For the month of May 2018
 
Commission File Number: 001-11960
 
AstraZeneca PLC
 
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F X Form 40-F __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes __ No X
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 
 
 
 
 
AstraZeneca PLC
 
INDEX TO EXHIBITS
 
 
1.
(Result of AGM)
 
18 May 2018 17:30 BST
 
Results of Annual General Meeting held on 18 May 2018
 
AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 1 - 8 were passed as ordinary resolutions and resolutions 9 - 13 were passed as special resolutions.
 
 
RESOLUTION
 
VOTES FOR
 
% OF VOTES CAST
 
VOTES AGAINST
 
% OF VOTES CAST
 
VOTES CAST IN TOTAL
 
TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL
 
VOTES WITHHELD
 
1
 
To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2017
 
 
975,352,556
99.97
286,020
0.03
975,638,576
77.03%
2,190,628
2
 
To confirm dividends
 
 
973,207,907
99.66
3,276,414
0.34
976,484,321
77.09%
1,345,238
3
 
To reappoint PricewaterhouseCoopers LLP as Auditor
 
 
975,991,837
99.92
823,912
0.08
976,815,749
77.12%
1,010,316
4
 
To authorise the Directors to agree the remuneration of the Auditor
 
 
975,217,035
99.83
1,642,984
0.17
976,860,019
77.12%
966,821
5a
 
To re-elect Leif Johansson as a Director
 
 
965,159,252
98.78
11,893,311
1.22
977,052,563
77.14%
777,040
5b
 
To re-elect Pascal Soriot as a Director
 
 
976,561,635
99.96
423,451
0.04
976,985,086
77.13%
840,934
5c
 
To re-elect Marc Dunoyer as a Director
 
 
966,288,665
98.93
10,404,129
1.07
976,692,794
77.11%
1,131,405
5d
 
To re-elect Geneviève Berger as a Director
 
 
969,536,507
99.27
7,178,145
0.73
976,714,652
77.11%
1,111,156
5e
 
To re-elect Philip Broadley as a Director
 
 
976,367,428
99.97
321,290
0.03
976,688,718
77.11%
1,137,091
5f
 
To re-elect Graham Chipchase as a Director
 
 
881,989,499
92.80
68,391,901
7.20
950,381,400
75.03%
27,446,864
5g
 
To elect Deborah DiSanzo as a Director
 
 
976,385,364
99.97
318,846
0.03
976,704,210
77.11%
1,122,657
5h
 
To re-elect Rudy Markham as a Director
 
 
963,170,539
98.61
13,530,376
1.39
976,700,915
77.11%
1,129,638
5i
 
To elect Sheri McCoy as a Director
 
 
976,377,268
99.97
302,558
0.03
976,679,826
77.11%
1,148,061
5j
 
To elect Nazneen Rahman as a Director
 
 
975,580,506
99.89
1,085,775
0.11
976,666,281
77.11%
1,161,656
5k
 
To re-elect Shriti Vadera as a Director
 
 
974,721,822
99.80
1,938,806
0.20
976,660,628
77.11%
1,168,365
5l
 
To re-elect Marcus Wallenberg as a Director
 
 
728,805,452
77.48
211,832,691
22.52
940,638,143
74.26%
37,189,833
6
 
To approve the Annual Report on Remuneration for the year ended 31 December 2017
 
 
616,320,491
65.08
330,706,327
34.92
947,026,818
74.77%
30,798,857
7
 
To authorise limited political donations
 
 
951,435,712
97.85
20,941,516
2.15
972,377,228
76.77%
5,450,018
8
 
To authorise the Directors to allot shares
 
 
879,235,003
90.02
97,511,636
9.98
976,746,639
77.11%
1,081,345
9
 
To authorise the Directors to disapply pre-emption rights
 
 
964,350,714
98.99
9,859,917
1.01
974,210,631
76.91%
3,617,671
10
 
To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments
 
 
948,470,583
97.36
25,722,825
2.64
974,193,408
76.91%
3,633,732
11
 
To authorise the Company to purchase its own shares
 
 
964,157,201
98.76
12,138,730
1.24
976,295,931
77.08%
1,532,147
12
 
To reduce the notice period for general meetings
 
 
887,046,924
91.22
85,341,411
8.78
972,388,335
76.77%
5,438,953
13
 
To adopt new Articles of Association
 
 
962,268,146
99.00
9,709,546
1.00
971,977,692
76.74%
5,848,152
 
AstraZeneca is pleased to have received shareholder support for all resolutions proposed at the AGM, but is disappointed with the lower level of support received for its Annual Report on Remuneration for the year ended 31 December 2017.
 
AstraZeneca engaged with its major shareholders during 2017 and is disappointed that enhancements made to Remuneration Report disclosures and changes to the operation of the annual bonus scheme in response to shareholder feedback have not significantly improved the voting result.
 
The Remuneration Committee has already engaged with a number of shareholders to understand the reasoning behind their decisions not to support the Remuneration Report and will continue to engage with shareholders during 2018 to determine how best to address their concerns.
 
Issued capital
As at 16 May 2018, the number of issued shares of the Company was 1,266,635,735 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.
 
Adrian Kemp
Company Secretary, AstraZeneca PLC
18 May 2018
 
 
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
 
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
 
Media Relations
 
 
Karen Birmingham
UK/Global
+44 203 749 5634
Rob Skelding
UK/Global
+44 203 749 5821
Matt Kent
UK/Global
+44 203 749 5906
Gonzalo Viña
UK/Global
+44 203 749 5916
Jacob Lund
Sweden
+46 8 553 260 20
Michele Meixell
US
+1 302 885 2677
 
 
 
Investor Relations
 
 
Thomas Kudsk Larsen
 
+44 203 749 5712
Craig Marks
Finance; Fixed Income; M&A
+44 7881 615 764
Henry Wheeler
Oncology
+44 203 749 5797
Mitchell Chan
Oncology; Other
+1 240 477 3771
Christer Gruvris
Brilinta; Diabetes
+44 203 749 5711
Nick Stone
Respiratory; Renal
+44 203 749 5716
US toll free
 
+1 866 381 7277
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
 
 
Date: 18 May 2018
 
 
By: /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary